Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cells

Molecular Medicine Reports

Volumn 4, Issue 4, 2011, Pages 753-757

  Xing, Xi Qian ^a   Shu, Duan ^b   Wu, Xu Wei ^a   Gan, Ye ^b   Zhao, Shui Ping ^b   Ping, Chen ^b   Wu, Shang Jie ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

C reactive protein; Human lung epithelial cell; Lipopolysaccharide; Lung inflammation; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG ALVEOLUS EPITHELIUM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL CELLS; HEPTANOIC ACIDS; HUMANS; LIPOPOLYSACCHARIDES; PYRROLES;

EID: 79957650480     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.491     Document Type: Article

References (40)

1. Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999. (Pubitemid 29084777)
2. Claus DR, Osmand AP and Gewurz H: Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 87: 120-128, 1976.
3. Peng N, Liu JT, Gao DF, Lin R and Li R: Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 193: 292-298, 2007. (Pubitemid 47058117)
4. Jabs WJ, Logering BA, Gerke P, et al: The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33: 152-161, 2003. (Pubitemid 36157653)
5. Ouchi N, Kihara S, Funahashi T, et al: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107: 671-674, 2003. (Pubitemid 36222590)
6. Yasojima K, Schwab C, McGeer EG and McGeer PL: Human neurons generate C-reactive protein and amyloid P: up-regulation in Alzheimer's disease. Brain Res 887: 80-89, 2000. (Pubitemid 32008026)
7. Gould JM and Weiser JN: Expression of C-reactive protein in the human respiratory tract. Infect Immun 69: 1747-1754, 2001. (Pubitemid 32187634)
8. Ramage L and Guy K: Expression of C-reactive protein and heat-shock protein-70 in the lung epithelial cell line A549, in response to PM10 exposure. Inhal Toxicol 16: 447-452, 2004. (Pubitemid 38685136)
9. Ramage L, Proudfoot L and Guy K: Expression of C-reactive protein in human lung epithelial cells and up-regulation by cytokines and carbon particles. Inhal Toxicol 16: 607-613, 2004. (Pubitemid 38988742)
10. Watterson TL, Hamilton B, Martin R and Coulombe RA Jr: Urban particulate matter causes ER stress and the unfolded protein response in human lung cells. Toxicol Sci 112: 111-122, 2009.
11. Wu SJ and Zhao SP: [Clinical observation and expression of C-reactive protein by LPS-induced A549 cells in patients with chronic obstructive pulmonary disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (In Chinese) 30: 207-210, 2005.
12. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
13. Hebert PR, Gaziano JM, Chan KS and Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321, 1997. (Pubitemid 27339660)
14. Scandinavian Simvastatin Survival Study: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344: 1383-1389, 1994.
15. Vaughan CJ, Murphy MB and Buckley BM: Statins do more than just lower cholesterol. Lancet 348: 1079-1082, 1996. (Pubitemid 26343606)
16. Muhlestein JB, Anderson JL, Horne BD, et al: Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 94: 1107-1112, 2004. (Pubitemid 39424210)
17. Albert MA, Danielson E, Rifai N and Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70, 2001. (Pubitemid 32606333)
18. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29-38, 2005. (Pubitemid 40075678)
19. Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28, 2005. (Pubitemid 40075677)
20. Soyseth V, Brekke PH, Smith P and Omland T: Statin use is associated with reduced mortality in COPD. Eur Respir J 29: 279-283, 2007. (Pubitemid 46237383)
21. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM and Brophy JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47: 2554-2560, 2006. (Pubitemid 43866389)
22. Van Eeden SF, Tan WC, Suwa T, et al: Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med 164: 826-830, 2001. (Pubitemid 32881920)
23. Suresh MV, Singh SK and Agrawal A: Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem 279: 52552-52557, 2004. (Pubitemid 39656631)
24. Wu S, Duan S, Zhao S, Cai Y, Chen P and Fang X: Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respir Res 6: 27, 2005.
25. Arnaud C, Burger F, Steffens S, et al: Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25: 1231-1236, 2005. (Pubitemid 40776614)
26. Li J, Li JJ, He JG, Nan JL, Guo YL and Xiong CM: Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-κB pathway. Cardiovasc Ther 28: 8-14, 2010.
27. Chalmers JD, Singanayagam A, Murray MP and Hill AT: Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007.e1, 2008.
28. Van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM and Leufkens HG: Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61: 957-961, 2006. (Pubitemid 44787165)
29. Schlienger RG, Fedson DS, Jick SS, Jick H and Meier CR: Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27: 325-332, 2007. (Pubitemid 46327900)
30. Mortensen EM, Restrepo MI, Anzueto A and Pugh J: The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 6: 82, 2005.
31. Shyamsundar M, McKeown ST, O'Kane CM, et al: Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179: 1107-1114, 2009.
32. Gan WQ, Man SF, Senthilselvan A and Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574-580, 2004. (Pubitemid 38901515)
33. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A and Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 250-255, 2007. (Pubitemid 46203128)
34. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP and Sin DD: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61: 849-853, 2006. (Pubitemid 44570304)
35. De Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 27: 902-907, 2006.
36. Broekhuizen R, Wouters EF, Creutzberg EC and Schols AM: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61: 17-22, 2006. (Pubitemid 43106972)
37. Hurst JR, Donaldson GC, Perera WR, et al: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 867-874, 2006. (Pubitemid 44564786)
38. Lee TM, Lin MS and Chang NC: Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 101: 530-535, 2008.
39. Sedgwick JB, Menon I, Gern JE and Busse WW: Effects of inflammatory cytokines on the permeability of human lung micro-vascular endothelial cell monolayers and differential eosinophil transmigration. J Allergy Clin Immunol 110: 752-756, 2002. (Pubitemid 35423178)
40. Ochrietor JD, Harrison KA, Zahedi K and Mortensen RF: Role of STAT3 and C/EBP in cytokine-dependent expression of the mouse serum amyloid P-component (SAP) and C-reactive protein (CRP) genes. Cytokine 12: 888-899, 2000. (Pubitemid 30479470)